Dr. Reddy’s Laboratories has confirmed it is still awaiting the final ‘Notice of Compliance’ for its Semaglutide Injection from Health Canada. While the final approval is pending, the company successfully received the ‘Drug Identification Numbers (DINs)’ on April 22, 2026. Dr. Reddy’s continues to work with regulators to bring this product to the Canadian market.
Clarification on Regulatory Status
Following recent market reports, Dr. Reddy’s Laboratories has clarified its current progress regarding the regulatory approval for its Semaglutide Injection in Canada. The company confirmed that while the final ‘Notice of Compliance’ has not yet been issued, the project remains an active priority as part of its ongoing regulatory review process.
Progress Toward Canadian Market Entry
A significant milestone was reached on April 22, 2026, when the company received the ‘Drug Identification Numbers (DINs)’ for the injection. The acquisition of DINs is a vital step in the pharmaceutical regulatory pathway, indicating that the product is advancing through the necessary assessments. Dr. Reddy’s remains engaged with health authorities to finalize the remaining approval requirements, demonstrating a strong commitment to expanding its therapeutic portfolio in the Canadian market.
Source: BSE
